08:00 , Nov 11, 2010 |  BC Innovations  |  Targets & Mechanisms

Going APOA1 in cancer

Researchers at the University of California, Los Angeles and colleagues have shown that apolipoprotein A-1, the major component of high-density lipoprotein, could have a therapeutic effect in ovarian cancer.1Resverlogix Corp., a biotech with an apolipoprotein...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Artery Therapeutics, Roche deal

The companies will co-develop Artery's apolipoprotein A-1 (APOA1) peptide mimetics. The deal includes Artery's lead, AT5261, which is in preclinical testing to treat atherosclerosis and prevent cardiovascular events in patients who have suffered...
23:35 , Feb 12, 2010 |  BC Extra  |  Company News

Roche, Artery in APOA1 deal

Artery Therapeutics Inc. (Danville, Calif.) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to co-develop Artery's apolipoprotein A-1 (APOA1) peptide mimetics. The deal includes Artery's lead, AT5261, which is in preclinical testing to treat atherosclerosis and prevent cardiovascular...